Last update 21 Nov 2024

YP-01001

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
FGFRs x RET x VEGFR1 x VEGFR2 x VEGFR3
Mechanism
FGFRs antagonists(Fibroblast growth factor receptors antagonists), RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors), VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists)
+ [2]
Therapeutic Areas
NeoplasmsEndocrinology and Metabolic DiseaseOther Diseases
Active Indication
Solid tumorAdvanced Malignant Solid NeoplasmThyroid Cancer
Inactive Indication-
Originator Organization
Chongqing Yao Pharmaceutical Co., Ltd.Chongqing Yao Pharmaceutical Co., Ltd.
Active Organization
Chongqing Yao Pharmaceutical Co., Ltd.Chongqing Yao Pharmaceutical Co., Ltd.Shanghai Fosun Pharmaceutical (Group) Co., Ltd.Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with YP-01001
CTR20211681 / Active, not recruitingPhase 1
评价YP01001胶囊在晚期实体瘤（甲状腺癌和其他实体瘤）患者中的安全性、耐受性、药代动力学特征及初步有效性的开放、多中心、剂量递增与扩展的I期临床试验
[Translation] An open, multicenter, dose-escalation and expansion Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of YP01001 capsules in patients with advanced solid tumors (thyroid cancer and other solid tumors)
100 Clinical Results associated with YP-01001
Login to view more data
100 Translational Medicine associated with YP-01001
Login to view more data
100 Patents (Medical) associated with YP-01001
Login to view more data
100 Deals associated with YP-01001
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Solid tumorPhase 2
CN
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
-
Advanced Malignant Solid NeoplasmPhase 1
CN
Chongqing Yao Pharmaceutical Co., Ltd.Chongqing Yao Pharmaceutical Co., Ltd.
26 Jul 2021
Thyroid CancerPhase 1
CN
Chongqing Yao Pharmaceutical Co., Ltd.Chongqing Yao Pharmaceutical Co., Ltd.
26 Jul 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free